Skip to content
TriangleGet started
← Indolent B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Indolent, Recurrent B-Cell NHL

Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Indolent, Recurrent B-Cell Non-Hodgkin Lymphoma

Treatment options for indolent, recurrent B-cell NHL include:

Rituximab alone or in combination with cytotoxic agents used in front-line therapy.

Source links and citations

Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy.

Source links and citations

Lenalidomide and rituximab.

Source links and citations

Zanubrutinib and obinutuzumab.

Source links and citations

EZH2 inhibitor.

Source links and citations

EZH2 inhibitor.

Tazemetostat.

Source links and citations

Bispecific T-cell engagers.

Source links and citations

Bispecific T-cell engagers.

Mosunetuzumab.

Source links and citations

Bispecific T-cell engagers.

Epcoritamab.

Source links and citations

Chimeric antigen receptor (CAR) T-cell therapy.

Source links and citations

Stem cell transplant (SCT).

Source links and citations

Palliative radiation therapy.

Source links and citations

Continue within this section

Rituximab alone or in combination with cytotoxic agents used in front-line therapy →Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy →Lenalidomide and rituximab →Zanubrutinib and obinutuzumab →EZH2 inhibitor →Bispecific T-cell engagers →Chimeric antigen receptor (CAR) T-cell therapy →Stem cell transplant →Palliative radiation therapy →

Preserved source evidence · Independent clinical review pending · Not medical advice